Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

AIMS The purpose of this paper is to investigate the effect of bevacizumab (BEV) on the diffusion properties of irradiated brain gliomas. MATERIALS & METHODS Neuroimaging studies and medical records of 44 patients undergoing treatment for cerebral gliomas were reviewed. MRIs were analyzed for presence of restricted diffusion, time to onset, pattern/location, duration of restriction, and persistence of restriction post-treatment with BEV. RESULTS Patchy confluent areas of diffusion restriction on MRI were found in 12 patients. All 12 patients received radiation therapy followed by BEV therapy. Diffusion restriction appeared 3 to 21 months after onset of radiation and 1 to 6 months after starting BEV therapy, increased in size over time, and persisted up to 23 months while on BEV. Restricted diffusion was observed in areas that received 60 Gy or more of radiation. Areas of restricted diffusion showed low T1 and increased T2 signal intensity, minimal or no contrast enhancement, and low cerebral blood volume. A thin perimeter of susceptibility outlined the restricted areas on susceptibility-weighted images in nine patients (75%). Small focal areas of tumor recurrence within larger regions of restricted diffusion were evident in only four patients (33%). In seven patients (58%) the area of restricted diffusion showed necrosis or radiation change on histology or no metabolic activity on MR spectroscopy or PET. CONCLUSION Restricted diffusion associated with BEV-treated cerebral gliomas occurs in regions of high-dose radiation and does not indicate high-cellularity of tumor recurrence.

[1]  J. Raizer,et al.  Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity , 2014, Journal of Neuro-Oncology.

[2]  Helen D'Arceuil,et al.  Probing tissue microstructure with restriction spectrum imaging: Histological and theoretical validation , 2013, Human brain mapping.

[3]  T. Cloughesy,et al.  Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls , 2012, American Journal of Neuroradiology.

[4]  A G Sorensen,et al.  Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.

[5]  P. Gutin,et al.  Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma , 2011, American Journal of Neuroradiology.

[6]  Tracy T Batchelor,et al.  Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.

[7]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Hattingen,et al.  Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients , 2010, Journal of Neuro-Oncology.

[9]  T. Mikkelsen,et al.  Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker , 2010, Journal of Neuro-Oncology.

[10]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[11]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Server,et al.  Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema , 2009, Acta radiologica.

[13]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[14]  A. Brandes,et al.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.

[15]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[16]  Thomas L Chenevert,et al.  Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. , 2006, Magnetic resonance imaging.

[17]  K. Kono,et al.  The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.

[18]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[19]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.